Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 50Years
All Genders
Healthy Volunteers
NCT07179640

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Led by Alesta Therapeutics · Updated on 2026-01-30

120

Participants Needed

2

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia (HPP).

CONDITIONS

Official Title

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Who Can Participate

Age: 18Years - 50Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants are overtly healthy as determined by a medical evaluation
  • No concurrent medical conditions or significant medical history, in the opinion of the investigator
  • Documented ALPL gene variant
Not Eligible

You will not qualify if you...

  • History of conditions affecting bone or mineral metabolism
  • Previous treatment with enzyme replacement therapy or advanced therapies (e.g., gene therapy) for HPP or treatments for osteoporotic diseases
  • Previous exposure to medications or investigational agents affecting bone structure, muscle volume, strength, or nerve function
  • Diagnosis of hyperparathyroidism
  • Diagnosis of hypoparathyroidism unless secondary to HPP
  • New fracture within 12 weeks before first dosing

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

New Zealand Clinical Research

Grafton, Auckland, New Zealand, 1010

Actively Recruiting

2

Fortrea Clinical Research Unit

Leeds, United Kingdom

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here